Khuong Chau Quang

Row 1 · 2023-06-14 · Grant · Acquired 18,000 · Balance 18,000

F1: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 14, 2023, the date of the Issuer's 2023 Annual Meeting of Stockholders, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date.

Row 1 · 2023-06-14 · Grant · Acquired 17,000 · Balance 17,000

F1: This option fully vests on the earlier of (i) June 14, 2024 or (ii) the 2024 Annual Meeting of Shareholders of Fusion Pharmaceuticals Inc.

Row 1 · 2020-10-09 · Grant · Acquired 91 · Balance 1,875

F1: Represents shares of common stock received in lieu of cash fees pursuant to the Issuer's Non-Employee Director Compensation Policy.

F2: Pursuant to an agreement with OrbiMed Advisors LLC ("Advisors") and OrbiMed Capital GP V LLC ("GP V"), the Reporting Person is obligated to transfer these securities, or the economic benefit thereof, to Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP ("OPI V").

Row 1 · 2017-06-23 · Other · Acquired 1,677,940 · Balance 1,677,940

F1: Reflects the beneficial ownership of the reporting person following the succession pursuant to Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended, of Nabriva Therapeutics plc to Nabriva Therapeutics AG. The succession occurred following the conclusion, on June 23, 2017, of a tender offer related to the exchange of American depositary shares and common shares of Nabriva Therapeutics AG for ordinary shares of Nabriva Therapeutics plc.

F2: These shares are held of record by OrbiMed Private Investments V, LP ("OPI V"). OrbiMed Advisors LLC ("Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the sole managing member of OrbiMed Capital GP V LLC ("GP V"), which is the sole general partner of OPI V, which is the majority member of OrbiMed Private Investments V Cooperatief U.A. ("OPI V Cooperatief"), which is the sole shareholder of OrbiMed Private Investments V-NB B.V. ("OPI V- NB"). OPI V and OPI V-NB hold ADSs and Common Shares, respectively, as described herein. Samuel D. Isaly ("Isaly"), a natural person, is the managing member of Advisors and owns a controlling interest in Advisors.

F3: The Reporting Person, an employee of Advisors, has been designated by Advisors to serve on the issuer's board of directors and disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act") except to the extent of his pecuniary interest therein, if any. This report on Form 3 shall not be deemed any admission that any such entity or person, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act or for any other purpose.

Row 2 · 2017-06-23 · Other · Acquired 2,241,660 · Balance 2,241,660

F1: Reflects the beneficial ownership of the reporting person following the succession pursuant to Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended, of Nabriva Therapeutics plc to Nabriva Therapeutics AG. The succession occurred following the conclusion, on June 23, 2017, of a tender offer related to the exchange of American depositary shares and common shares of Nabriva Therapeutics AG for ordinary shares of Nabriva Therapeutics plc.

F3: The Reporting Person, an employee of Advisors, has been designated by Advisors to serve on the issuer's board of directors and disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act") except to the extent of his pecuniary interest therein, if any. This report on Form 3 shall not be deemed any admission that any such entity or person, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act or for any other purpose.

F4: These shares are held of record by OPI V-NB.

Row 3 · 2017-06-23 · Other · Acquired 10,100 · Balance 10,100

F5: The exercise price is 6.634 Euro.

F2: These shares are held of record by OrbiMed Private Investments V, LP ("OPI V"). OrbiMed Advisors LLC ("Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the sole managing member of OrbiMed Capital GP V LLC ("GP V"), which is the sole general partner of OPI V, which is the majority member of OrbiMed Private Investments V Cooperatief U.A. ("OPI V Cooperatief"), which is the sole shareholder of OrbiMed Private Investments V-NB B.V. ("OPI V- NB"). OPI V and OPI V-NB hold ADSs and Common Shares, respectively, as described herein. Samuel D. Isaly ("Isaly"), a natural person, is the managing member of Advisors and owns a controlling interest in Advisors.

F6: This option was granted on August 26, 2016. Vesting began on August 31, 2016 and ends on August 31, 2017. One hundred percent (100%) of the option will vest on August 31, 2017.

Row 1 · Balance 167,794

F1: Represented by 1,677,940 American Depositary Shares ("ADSs").

F2: These shares are held of record by OrbiMed Private Investments V, LP ("OPI V"). OrbiMed Advisors LLC ("Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the sole managing member of OrbiMed Capital GP V LLC ("GP V"), which is the sole general partner of OPI V, which is the majority member of OrbiMed Private Investments V Cooperatief U.A. ("OPI V Cooperatief"), which is the sole shareholder of OrbiMed Private Investments V-NB B.V. ("OPI V- NB"). OPI V and OPI V-NB hold ADSs and Common Shares, respectively, as described herein. Samuel D. Isaly ("Isaly"), a natural person, is the managing member of Advisors and owns a controlling interest in Advisors.

F3: The Reporting Person, an employee of Advisors, has been designated by Advisors to serve on the issuer's board of directors and disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act") except to the extent of his pecuniary interest therein, if any. This report on Form 3 shall not be deemed any admission that any such entity or person, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act or for any other purpose.

Row 2 · Balance 224,166

F3: The Reporting Person, an employee of Advisors, has been designated by Advisors to serve on the issuer's board of directors and disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act") except to the extent of his pecuniary interest therein, if any. This report on Form 3 shall not be deemed any admission that any such entity or person, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act or for any other purpose.

F4: These shares are held of record by OPI V-NB.

Row 3 · Balance Not disclosed

F6: The exercise price is 66.34 Euro.

F5: This option was granted on August 26, 2016. Vesting began on August 31, 2016 and ends on August 31, 2017. One hundred percent (100%) of the option will vest on August 31, 2017.

Row 1 · 2023-06-22 · Grant · Acquired 14,250 · Balance 14,250

F1: The option vests in full on the earlier of June 22, 2024 and the date of the 2024 Annual Meeting of Stockholders.

Row 1 · 2017-10-25 · Grant · Acquired 6,115 · Balance 6,115

F1: The Reporting Person is an employee of OrbiMed Advisors LLC ("Advisors") and is obligated to transfer any shares issued under equity grants made to him by the Issuer, or the economic benefits thereof, to Advisors for the ultimate benefit of OrbiMed Private Investments III, LP and OrbiMed Associates III, LP.

Row 1 · 2021-04-20 · Grant · Acquired 1,666,666 · Balance 3,696,662

F1: These shares of the Issuer's common stock were sold in an underwritten public offering at a price of $3.00 per share.

F2: These shares of the Issuer's common stock are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP V") is the general partner of OPI VI, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VI. The Reporting Person is an employee of OrbiMed Advisors. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VI noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI VI.

F3: Each of the Reporting Person, GP VI, and OrbiMed Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, GP VI or OrbiMed Advisors is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes.

Row 1 · 2019-06-18 · Grant · Acquired 21,400 · Balance 21,400

F1: Options shall vest annually on the earlier of the one year anniversary of the Grant Date or the Company's next annual meeting, subject to director's continued service on the Board at such time.